

**AWARD NUMBER: W81XWH-20-1-0526**

**TITLE: CD8 T-Cell Infiltration as a Predictor of Renal Cancer Progression After Surgery**

**PRINCIPAL INVESTIGATOR: Viraj Master**

**CONTRACTING ORGANIZATION: Emory University, Atlanta, GA**

**REPORT DATE: October 2021**

**TYPE OF REPORT: Annual**

**PREPARED FOR: U.S. Army Medical Research and Development Command  
Fort Detrick, Maryland 21702-5012**

**DISTRIBUTION STATEMENT:** Approved for public release; distribution is unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

*Form Approved*  
*OMB No. 0704-0188*

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

<b>1. REPORT DATE</b> October 2021			<b>2. REPORT TYPE</b> Annual		<b>3. DATES COVERED</b> 15Sep2020-14Sep2021	
<b>4. TITLE AND SUBTITLE</b>  CD8 T-Cell Infiltration as a Predictor of Renal Cancer Progression After Surgery					<b>5a. CONTRACT NUMBER</b> W81XWH-20-1-0526	
					<b>5b. GRANT NUMBER</b>	
					<b>5c. PROGRAM ELEMENT NUMBER</b>	
<b>6. AUTHOR(S)</b>  Viraj Master  E-Mail:					<b>5d. PROJECT NUMBER</b>	
					<b>5e. TASK NUMBER</b>	
					<b>5f. WORK UNIT NUMBER</b>	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>  EMORY UNIVERSITY 201 DOWMAN DR ATLANTA GA 30322-1007					<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b>  U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012					<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>	
					<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>	
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b>  Approved for Public Release; Distribution Unlimited						
<b>13. SUPPLEMENTARY NOTES</b>						
<b>14. ABSTRACT</b>  The work in this proposal aims to determine how the level of CD8 T-cell infiltration into kidney tumors can be used to predict which patients will survive after surgery to remove their tumors. In addition, this project aims to study the basic mechanisms in kidney tumors that regulate the level of these important cells.						
<b>15. SUBJECT TERMS</b> None listed.						
<b>16. SECURITY CLASSIFICATION OF:</b>				<b>17. LIMITATION OF ABSTRACT</b>	<b>18. NUMBER OF PAGES</b>	<b>19a. NAME OF RESPONSIBLE PERSON</b>
<b>a. REPORT</b>	<b>b. ABSTRACT</b>	<b>c. THIS PAGE</b>		Unclassified	16	USAMRMC
Unclassified	Unclassified	Unclassified				<b>19b. TELEPHONE NUMBER</b> <i>(include area code)</i>

## TABLE OF CONTENTS

	<u>Page</u>
1. Introduction	4
2. Keywords	4
3. Accomplishments	4
4. Impact	8
5. Changes/Problems	9
6. Products	11
7. Participants & Other Collaborating Organizations	14
8. Special Reporting Requirements	16
9. Appendices	16

## 1. INTRODUCTION:

The work in this proposal aims to determine how the level of CD8 T-cell infiltration into kidney tumors can be used to predict which patients will survive after surgery to remove their tumors. In addition, this project aims to study the basic mechanisms in kidney tumors that regulate the level of these important cells.

## 2. KEYWORDS:

Kidney Cancer, T cells

## 3. ACCOMPLISHMENTS:

**What were the major goals of the project?**

Below are the major tasks proposed for this grant, and the subtasks assigned to year 1.

### **Major Task 1 Validate Immunofluorescence quantification of CD8 infiltration as a biomarker in RCC patients with T3/M0/N0 disease**

Subtask 1: Regulatory review of human subjects research by HRPO - **Complete**

Subtask 2: Collection of FFPE slides of 150 of T3N0M0 patients Emory University Hospital n=120, and the Atlanta VA hospital=30. **~60% complete (88 samples collected)**

Subtask 3: Immunofluorescence staining and image processing of 150 cases **50% complete**

Subtask 4: Obtain FFPE slides from Univ Wisconsin collaborator (Dr. Abel) - **ongoing**

### **Major Task 2 Investigate the predictive power of the CD8 infiltration in response to checkpoint therapies:**

No sub tasks proposed for year 1.

### **Major Task 3: Determine the role of de-novo generated fibroblastic reticular cells (FRCs) in the maintenance of a supportive antigen-presenting niche:**

Subtask 1: Functional capacity of FRCs to recruit dendritic cells and stem-like T-cells using in vitro assays. Fibroblasts and immune cells are sorted from banked human tumor samples and incubated in transwell plates. Ability of cells to migrate is assessed after either 4 or 24 hours. - **ongoing**

Subtask 2: Single cell RNAseq to define FRC lineage and features of cancer cells from hot and cold tumors (30 patients). Cells are sorted from previously banked human tumor samples and processed by the Emory Genomics core – **50% complete**

### **Major Task 4: Determine the role and development pathways of FRCs using mouse models**

Subtask 1: Regulatory review and approval of animal studies. - **complete**

Subtask 2: Do additional FRCs in the tumor help establish the antigen presenting niche. - **ongoing**

## What was accomplished under these goals?

### 1) Major activities

Major activities of this period were acquisition of kidney cancer slides from pathology and collaborators, RNAseq of fibroblasts from human tumors, beginning functional experiments using human fibroblasts.

### 2) Specific Objectives

See major goals section above for the specific objectives of this project.

### 3) Significant results

All aims of this project are in early phases and no final results from any experiments have been collected. Most of the first year has been optimizing protocols and performing initial experiments. Details are outlined below.

#### i) Optimization of tissue staining protocols

We spent the first 6 months optimizing a slightly new staining protocol that now allows us to stain up to 7 colors at a time to allow more detailed analysis. This procedure has been performed on 88 patients and we will continue to collect and stain the planned 150 patients from Emory and 100 from Wisconsin.





Fig 1: Kidney cancer slides are stained using the Opal protocol for the markers listed. Imaging of

entire slides are then taken using fluorescent slide scanner. This has been completed for 88 patients. Analysis for how various parameters correlate with patient survival is ongoing.

#### ii) Collection of RNAseq data from fibroblasts in human patients

Data has been collected from 19 patients. Data analysis is only preliminary to ensure it is of sufficient quality for future analysis. Full analysis will be completed once all the samples are collected.



#### iii) Begun in vitro functional assays using human fibroblasts

We have begun performing various functional experiments using human fibroblasts. The early part of this proposal was spent developing methods to effectively grow fibroblasts from human tumors in a manner that retained their phenotype. We found that an organoid 3d culture gave us the best results at expanding these cells. Ongoing experiments are optimizing the use of these fibroblasts to test their functionality to recruit different immune cell populations from the tumors. Data will be reported in the next progress report.

#### iv) Begun mouse experiments on fibroblasts

Experiments studying mouse fibroblasts are underway and we can detect these cells in mice. We are delaying functional experiments until better information is gathered from human RNAseq in the next ~6 months.

### 4) **Other achievements**

A staff scientist, Baohan Vo, was hired on this project and has made excellent progress completing the work outlined.

The only goal not met on time was collection of slides from our Wisconsin collaborator. This was delayed due to the MTA process taking longer than expected but is still well within the scope of the project.

**What opportunities for training and professional development has the project provided?**

Nothing to report

**How were the results disseminated to communities of interest?**

Nothing to report

**What do you plan to do during the next reporting period to accomplish the goals?**

Plans will continue as outlined in the statement of work. We do not foresee any deviations from the planned work

**4. IMPACT:**

**What was the impact on the development of the principal discipline(s) of the project?**

Nothing to report

**What was the impact on other disciplines?**

Nothing to report

**What was the impact on technology transfer?**

Nothing to report

**What was the impact on society beyond science and technology?**

Nothing to report

**5. CHANGES/PROBLEMS:**

Nothing to report

**Actual or anticipated problems or delays and actions or plans to resolve them**

Slow MTA approval by Emory and Wisconsin legal offices. These have mostly been approved and slides are being selected at Wisconsin to send to Emory in the next 3 months.

**Changes that had a significant impact on expenditures**

Nothing to report

**Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents**

**Significant changes in use or care of human subjects**

Nothing to report

**Significant changes in use of biohazards and/or select agents**

Nothing to report

**6. PRODUCTS:**

- **Publications, conference papers, and presentations**

**Journal publications.**

Nothing to report

**Books or other non-periodical, one-time publications.**

Nothing to report

**Other publications, conference papers and presentations.**

Nothing to report

- **Website(s) or other Internet site(s)**

Nothing to report

- **Technologies or techniques**

Nothing to report

- **Inventions, patent applications, and/or licenses**

Nothing to report

- **Other Products**

Nothing to report

## 7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

### What individuals have worked on the project?

Name: Haydn Kissick  
Project Role: PI  
Nearest person month worked: 2 months  
Contribution to Project: Oversight of project  
Funding support:

Name: Viraj Master  
Project Role: PI  
Nearest person month worked: 1  
Contribution to Project: Oversight of project  
Funding support:

Name: Baohan Vo  
Project Role: Scientist  
Nearest person month worked: 9  
Contribution to Project: Optimized and performed all staining of slides in Aim 1.  
Funding support: Additional funding support is provided by departmental funds.

Name: Yuan Liu  
Project Role: Biostatistician  
Nearest person month worked: 1  
Contribution to Project: Experimental design  
Funding support: NA

Name: Maria Cardenas

Project Role: Graduate Students

Nearest person month worked: 12

Contribution to Project: RNAseq, optimization of fibroblast experiments, mouse experiments

Funding support: NA

**Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?**

Nothing to report

**What other organizations were involved as partners?**

Nothing to report

**8. SPECIAL REPORTING REQUIREMENTS**

**COLLABORATIVE AWARDS:**

**QUAD CHARTS:**

**9. APPENDICES:**